US/UK/Canada

Share

About Us

Inhalation Sciences Sweden AB (publ.) develops and sells patented, highly innovative labtech equipment for inhalation research. Scientists using it can now know, with unprecedented accuracy, how particles behave in our lungs when we inhale them: whether new pollutants or life-saving drugs that power human development.

Pick a time period -
Tags ( Active)

Inhalation Sciences AB (publ) releases Q1 Report 2024

(Stockholm, Sweden, 28 May 2024) Inhalation Sciences AB announces that its Q1 Report for 2024 is now available on the company’s website.To read the whole report (in Swedish), visit: http://inhalation.se/investors/finansiella-rapporter/ CEO statement Our first quarter started out strong with an increased revenue of 17% compared to the same period the year before. We also have a continued improved operating profit through continuous cost control and a streamlined organization that is designed to reach profitability in the near term and deliver growth according to our plan. Through

Inhalation Sciences presents at well-received FDA public workshop GDUFA

On 20 May Inhalation Sciences AB CSO Per Gerde presented the company’s predictive tools for developing and assessing generic inhaled pharmaceuticals at the FDA’s public GDUFA (Generic Drug User Fee Amendments) webinar (as previously communicated on April 10, 2024). The webinar was well-attended and well-received by a large audience of specialist industry professionals.ISAB’s webinar session at the workshop was titled “Predictive Tools for Generic Product Development & Assessment”. It was held by ISAB CSO and Founder Per Gerde and ISAB’s Director of Projects Dr Maria Malmlöf. Engagement

Inhalation Sciences AB (publ) releases Annual Report 2023

Inhalation Sciences AB announces that its Annual Report for 2023 is now available on the company’s website.To read the whole report (in Swedish), visit: http://inhalation.se/investors/finansiella-rapporter/ CEO comments 2023 was another year in which we continued to take new market share and successfully deliver on our strategic goals. Over the past three years, revenue has increased steadily by 29% from 2021 to 2022 and now by 44% from 2022 to 2023. At the same time, we have also significantly improved our operating profit during the same period. With this positive development, we

Inhalation Sciences to present at FDA’s public workshop GDUFA on May 20th, 2024

Inhalation Sciences Sweden AB (ISAB) has been invited to provide a public comments presentation at the FDA’s public workshop GDUFA (Generic Drug User Fee Amendments) on May 20[th], 2024.The annual GDUFA Public Workshop is open and free to the public, and any member of the public may provide comments to the docket for the meeting or may provide their public comments in a prepared presentation, or as impromptu comments. The FDA routinely announces the workshop and provides information about how the public may provide comments. This includes information about how the public can submit a

Positive results of first-in-human clinical trial of PreciseInhale now published in European Journal of Pharmaceutical Sciences

(Stockholm, 11 March 2024) Positive results from Inhalation Sciences’ first-in-human clinical study of its aerosol generating system PreciseInhale® are now published in a peer-reviewed paper in the European Journal of Pharmaceutical Sciences. The results demonstrate that PreciseInhale® provides greater precision and control than aerosol dosing carried out with a standard commercial inhaler, and can be used for ‘regional targeting’, exposing specific regions of the lungs to a targeted aerosol. The topline results were first communicated on December 20, 2021.The paper is titled Regional lung

Inhalation Sciences AB (publ) releases Q4 / YE Report

(Stockholm, Sweden, 28 February 2024) Inhalation Sciences AB announces that its Q4 / Year End Report for 2023 is now available on the company’s website.To read the whole report (in Swedish), visit: http://inhalation.se/investors/finansiella-rapporter/ CEO statement 2023 was another year when we continued to capture new market shares and successfully deliver on our strategic goals. Over the past three years, revenue has increased steadily by 29% from 2021 to 2022 and now by 49% from 2022 to 2023. At the same time, we have also significantly improved our operating profit at a similar

Inhalation Sciences secures product service contract worth 47,000 Euro

(Stockholm, Sweden, 29 December,2023) Inhalation Sciences AB (ISAB) has secured a product service contract with a worth of 47,000 Euro on its instruments at the facilities of a large European pharma company. The order reaffirms the client’s strong commitment to its continuing use of ISAB instruments on their robust portfolio of inhaled therapies.The client is a long-standing ISAB customer. Its suite of in-house ISAB instruments has played an important role in developing its competitive and substantial pipeline of inhaled therapeutics. The new contract will cover the service and maintenance

Inhalation Sciences’ captures interest and interaction at its latest industry webinar ‘Inhaled Biologics’

(Stockholm, Sweden, 13 December 2023) Interest and interaction was high on December 11 at ISAB’s latest industry webinar, ‘Inhaled Biologics’. Over 200 scientists registered for the event, the latest in ISAB’s highly popular series, with attendees logging in from Europe, Asia and the US. The webinar was co-hosted by experts in the formulation and drying of biologics, Ziccum AB.On December 11 at 11AM EST ISAB held the latest in its popular series of co-hosted industry webinars. The series has become a regular fixture for many scientists working in inhaled therapeutics and drug development,

Inhalation Sciences signs collaboration agreement with leading Indian multinational pharma company

Inhalation Sciences AB (ISAB) has signed a collaboration agreement with a leading Indian multinational pharma company with a powerful respiratory portfolio and a major presence in over 80 markets worldwide. The company has chosen DissolvIt[®],[ ]ISAB’s in vitro dissolution and absorption module, for its Inhalation Research project.The company is ISAB’s first Indian client and is a highly agile, innovative multinational with a large number of development projects ongoing and a YoY R&D investment that has grown continuously over recent years. The Indian pharmaceutical industry as a whole is a

Inhalation Science's rights issue is fully registered

The rights issue in Inhalation Sciences Sweden AB (publ) ("ISAB" or the "Company") which ended on May 9, 2023 has been finally registered. The second and last partial registration of the rights issue has been registered with the Swedish Companies Registration Office on July 6, 2023.THIS DOCUMENT IS NOT TO BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE SUBJECT TO LEGAL

Inhalation Sciences receives Purchase Order worth 125.8 KEURO from international distributor for Asia

Inhalation Sciences AB (ISAB) has received a Purchase Order, worth 125.8 KEuro (1.47 MSEK), from an international distributor for Asia. The new order is for PreciseInhale, ISAB’s unique aerosol generation system, with additional modules.PreciseInhale is unique within inhaled drug development as a ‘precision dosing’ system. Unlike standard ‘tower testing’ systems, it customizes the individual aerosol dose to individual test animals, achieving exceptionally high-precision and predictive data in the preclinical stages of inhaled drug development. ISAB has recently increased the focus of its

Inhalation Sciences receives 125,000 EURO funding in cross-European research project on inhaled antibiotics and antibiotic resistance

(Stockholm, 25 May, 2023) Inhalation Sciences (ISAB) has been awarded 125,000 EURO for its role in the research project ‘New Inhalation Formulations for Improved Delivery of Antimicrobials’ (APRINHA). ISAB is one of seven organizations collaborating on this project, including RISE (the Research Institutes of Sweden.) ISAB announced that it had collaborated with RISE on a joint funding proposal for the project on June 9, 2022. The project will run for 36 months. It is being coordinated by the University of Zurich (UZH).The unmet need for a targeted, efficacious inhaled antibiotic treatment

Inhalation Sciences receives new order worth 53,000 Euro from returning customer

Inhalation Sciences AB (ISAB) has received a new order worth 53,000 Euro from a regular client – a large global player in the field of inhaled therapies with a strong development pipeline based in Europe. The order is for additional modules and accessories that will expand the client’s two existing PreciseInhale systems.The client is a loyal ISAB customer, with two PreciseInhale systems in place. The client’s team carry out advanced in vivo work on New Chemical Entities, using the highly accurate preclinical data generated by PreciseInhale to significantly reduce risk in the later clinical

Inhalation Sciences receives green light from the US FDA to start the experimental phase of FDA BAA dissolution research project

(Stockholm, 05 May 2023) Following its communication on April 18, 2023, regarding completion of the required administrative routines necessary to proceed with its FDA BAA (Broad Agency Announcement) contract research project, ISAB today announces that it has now received the formal clearance to begin the experimental phase of the study. The study is now commencing at the company’s facilities in Sweden.The objective of contract 75F40122C00197 is to evaluate the discriminative power of ISAB’s DissolvIt technology by comparing drug formulations, aimed for administration via inhalation, with

Inhalation Sciences: close to 200 register for latest expert’s webinar - now available online

(Stockholm, Sweden, 4 May 2023) Almost 200 specialists registered for ISAB’s latest experts’ webinar, now available to view online on ISAB’s LinkedIn page. The webinar was co-hosted by ISAB CSO Per Gerde and Matt Reed from Coelus Bio. It demonstrated how high-precision preclinical in vivo data can provide more accurate clinical estimates that reduce risk in the clinical development of inhaled medicines.The webinar took place on May 2[nd], 2023. It was co-hosted by Matt Reed from Coelus Bio - a pharmacologist and board-certified toxicologist with over 25 years’ experience. The webinar was

Inhalation Sciences provides comments on the start of 2023

2023 has started in line with our expectations and we continue to see a steady inflow of inquiries from various biopharma customers and good progress in ongoing collaborations. We look forward to a spring and summer represented by a high-level of customer activity including several value-creating activities to continue our growth projectory.The year has started off with a signed customer order of over SEK 900,000 from a new US customer who develops targeted antiviral therapies. This customer's first project will use ISAB's DissolvIt module to perform solubility tests, with the goal of

Inhalation Sciences receives IRS order worth 35,000 Euro from global generics company

Inhalation Sciences AB (ISAB) has received an order from a new client, a global generics company, for an Inhalation Research Services (IRS) project. The client has chosen ISAB’s DissolvIt[®] for the project, due to its outstanding accuracy in testing generic formulations against originator products to define bioequivalence and, potentially, IVIVC (In Vitro In Vivo correlation), both critical metrics in generic drug development.The new client’s development team are highly expert and experienced in Pharmacokinetics (PK), bioequivalence and dissolution studies. They have chosen ISAB’s

Inhalation Sciences AB (publ) presents at Stockholm Corporate Finance 15th Life Science Capital Markets Days

Inhalation Sciences will take part in the Stockholm Corporate Finance 15th Life Science Capital Markets Days on 8 - 9 March 2023 at IVA Conference Center in Stockholm. CEO Manoush Masarrat will present the latest developments and the future of the company on March 9 at 10:00 am.Stockholm Corporate Finance Stockholm Corporate Finance is organising the Capital Markets Days for the fifteenth consecutive year in collaboration with Financial Hearings and Infront Direkt Studios, an independent part of Nyhetsbyrån Direkt.  If you would like to register as a participant for the Capital Markets Day,

Inhalation Sciences receives IRS order worth 118,464 Euro from US client following 50,000 Euro deposit

(Stockholm, Sweden, 7 March 2023) On 7 February 2023 Inhalations Sciences AB (ISAB) announced that a returning US client had paid a 50,000 Euro deposit to book lab time and facilities in April 2023 for an Inhalation Research Services’ R&D project. The client has now confirmed the entire IRS order, totaling 118,484 Euro (approx. 1.3 MSEK), of which 50,000 Euro has already been paid.A returning ISAB client, a mid-size US pharma company, has confirmed an IRS order worth 118,484 Euros in total following an advanced payment in February of 50,000 Euro. The client has chosen ISAB’s high-

Inhalation Sciences AB (publ) releases Year-End Report 2022

(Stockholm, Sweden, 28 February 2023) Inhalation Sciences AB announces that its Year-End Report for 2022 is now available on the company’s website. To read the whole report (in Swedish), visit: http://inhalation.se/investors/finansiella-rapporter/Summary of Year-End Report · Net revenue for the full year 2022 increased by 29% compared to 2021 · Sales for the full year 2022 increased by 74% compared to 2021 · Sales for Q4 2022 increased by 23% compared to the same period in 2021 · The company had an order backlog of SEK 9.1M in December 2022 compared to SEK 5M in the same

Inhalation Sciences receives advanced booking payment for upcoming IRS project in April 2023

A returning US client of Inhalation Sciences AB (ISAB) will pay a 50,000 Euro deposit to book lab time and facilities in April 2023 for an Inhalation Research Services’ R&D project. The total value of the entire project will be confirmed later. The client has chosen ISAB’s high-precision, specially tailored IPL (Isolated Perfused Lung) method for the IRS project.A mid-size US pharma company that is a returning ISAB client, will make an advanced payment of 50,000 Euro to book the company’s IRS team and IPL facilities for project work in April 2023. The total value of the project will be

Inhalation Sciences receives IRS order worth over 914,000 SEK from new US pharma customer

Inhalation Sciences AB (ISAB) has received an order worth over 914,000 SEK (81,200 Euros) for an Inhalation Research Service (IRS) project from a new US customer developing targeted antiviral therapies. In this first project they have chosen to use the DissolvIt[®] module to carry out dissolution testing, due to its exceptional accuracy which can reduce risk and attrition in later drug development.ISAB has received an order from a new customer, a cutting-edge US pharmaceutical company developing novel antiviral therapies to treat a range of viral diseases from influenza to COVID-19.

DDL2022: Inhalation Sciences had several landmark presentations at well-attended event

At this year’s DDL in Edinburgh, Scotland (7-9 December) Inhalation Sciences AB (ISAB) presented, for the first time, data from its clinical study of PreciseInhale, showing how the system out-performed commercial inhalers in targeting aerosols to specified regions of the lung. A second poster on ISAB’s in vitro simulation module DissolvIt was also presented. This was the first onsite DDL event since the end of European Covid-19 restrictions.DDL conferences (Drug Delivery to the Lungs) are some of the most well-attended events in the global inhalation industry’s calendar. As the first DDL

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe